Isolation and partial characterization of a human alveolar macrophage-derived neutrophil-activating factor.

Human alveolar macrophages (AM) were obtained from eight normal volunteers using fiberoptic bronchoscopic lavage to explore potential interrelationships among leukocytes in pulmonary defense against infection. AM placed in monolayer tissue cultures released material into culture supernatants with the capacity to enhance the bactericidal capacity of human neutrophils. Neutrophils preexposed to supernatants killed Pseudomonas aeruginosa from 70 to 90% more efficiently than control cells (P less than 0.02). AM culture supernatants contained this material by 4 h of incubation, and in vitro stimulation of AM cultures with heat-killed P. aeruginosa further increased its production. Gel filtration of AM culture supernatants with a G-50 Sephadex column allowed isolation of a 6,000-D neutrophil-activating factor (NAF) that was resistant to heat (56 degrees C, 30 min). The isoelectric point of NAF, as determined by chromatofocusing, was approximately 7.6. Enzyme digestion of NAF specimens, prepared sequentially by gel filtration and chromatofocusing, demonstrated 50-70% loss of activity after incubations with trypsin, chymotrypsin, and neuraminidase. NAF was only minimally chemotactic and eluted from Sephadex G-50 with particles of a different molecular size than those of AM-derived chemotactic factors (i.e., approximately 10,000 D and less than 500 D). Preincubation of neutrophils with NAF resulted in greater release of superoxide anion upon their subsequent stimulation by either bacterial phagocytosis or by phorbol myristate acetate, as compared with control neutrophils stimulated in a like manner. These studies indicate that human AM secrete a heat-stable, low molecular weight basic protein, with the capacity to enhance oxidative microbicidal activity of neutrophils.

[1]  F. Brodsky,et al.  Monoclonal antimacrophage antibodies: human pulmonary macrophages express HLA-DR (Ia-like) antigens in culture. , 2015, The American review of respiratory disease.

[2]  R. Crystal,et al.  Normal human alveolar macrophages obtained by bronchoalveolar lavage have a limited capacity to release interleukin-1. , 1984, The Journal of clinical investigation.

[3]  Hunninghake Gw Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. , 1984 .

[4]  E. Corey,et al.  Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. , 1984, The Journal of biological chemistry.

[5]  G. Toews,et al.  The accessory cell function of human alveolar macrophages in specific T cell proliferation. , 1984, Journal of immunology.

[6]  J. Pennington,et al.  The effect of human alveolar macrophages on the bactericidal capacity of neutrophils. , 1983, The Journal of infectious diseases.

[7]  W. J. Matthews,et al.  Complement biosynthesis by human bronchoalveolar macrophages. , 1983, Clinical immunology and immunopathology.

[8]  N. Pawlowski,et al.  Human alveolar macrophages produce leukotriene B4. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Weissmann,et al.  Leukotriene B4 is a complete secretagogue in human neutrophils: a kinetic analysis. , 1982, Biochemical and biophysical research communications.

[10]  J. Salmon,et al.  A radioimmunoassay for leukotriene B4. , 1982, Prostaglandins.

[11]  H. Colten,et al.  Biosynthesis and processing of a human precursor complement protein, pro-C3, in a hepatoma-derived cell line. , 1982, Science.

[12]  J. Pennington,et al.  Influence of immunosuppression on alveolar macrophage chemotactic activities in guinea pigs. , 1981, The American review of respiratory disease.

[13]  E. Corey,et al.  Leukotriene B. Total synthesis and assignment of stereochemistry , 1980 .

[14]  E. Corey,et al.  Total Synthesis of 6-Trans, 10-cis and (plus or minus) -6-Trans,8-cis Isomers of Leukotriene B , 1980 .

[15]  R. Crystal,et al.  Human alveolar macrophage-derived chemotactic factor for neutrophils. Stimuli and partial characterization. , 1980, The Journal of clinical investigation.

[16]  D. V. Van Epps,et al.  Enhancement of neutrophils function as a result of prior exposure to chemotactic factor. , 1980, The Journal of clinical investigation.

[17]  R. Matthay,et al.  Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization. , 1980, The Journal of clinical investigation.

[18]  V. Ferrans,et al.  Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. , 1979, The American journal of pathology.

[19]  W. Henderson,et al.  Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. , 1979, The Journal of clinical investigation.

[20]  J. Pennington,et al.  Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections , 1979, Infection and immunity.

[21]  M. Frank The complement system in host defense and inflammation. , 1979, Reviews of infectious diseases.

[22]  A. Issekutz,et al.  Enhancement of Human Neutrophil Bactericidal Activity by Chemotactic Factors , 1979, Infection and immunity.

[23]  L. Simchowitz,et al.  Generation of superoxide radicals by human peripheral neutrophils activated by chemotactic factor. Evidence for the role of calcium. , 1979, The Journal of laboratory and clinical medicine.

[24]  J. Pennington,et al.  Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression. , 1978, The Journal of infectious diseases.

[25]  D. Roos,et al.  Quantitative aspects of the production of superoxide radicals by phagocytizing human granulocytes. , 1975, The Journal of laboratory and clinical medicine.

[26]  J. Pennington,et al.  Granulocyte transfusion therapy of experimental Pseudomonas pneumonia. , 1974, The Journal of clinical investigation.

[27]  E. Goldstein,et al.  Pulmonary alveolar macrophage. Defender against bacterial infection of the lung. , 1974, The Journal of clinical investigation.

[28]  B. Babior,et al.  Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. , 1973, The Journal of clinical investigation.

[29]  S. Zigmond,et al.  LEUKOCYTE LOCOMOTION AND CHEMOTAXIS , 1973, The Journal of experimental medicine.

[30]  E. Wiener,et al.  THE PARTICULATE HYDROLASES OF MACROPHAGES , 1963, The Journal of experimental medicine.

[31]  L. Warren,et al.  The thiobarbituric acid assay of sialic acids. , 1959, The Journal of biological chemistry.

[32]  W. Henderson,et al.  Leukotriene B4 production by the human alveolar macrophage: a potential mechanism for amplifying inflammation in the lung. , 1984, The American review of respiratory disease.

[33]  G. Hunninghake Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. , 1984, The American review of respiratory disease.

[34]  C. Fanta,et al.  Fever and new lung infiltrates in the immunocompromised host. , 1981, Clinics in chest medicine.

[35]  H. B. Kaltreider Expression of immune mechanisms in the lung. , 1976, The American review of respiratory disease.

[36]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .

[37]  O OUCHTERLONY,et al.  Diffusion-in-gel methods for immunological analysis. , 1958, Progress in allergy.